Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors
Toshio Shimizu, John Powderly, Albiruni Abdul Razak, Patricia LoRusso, Kathy D. Miller, Steven Kao, Sarah Kongpachith, Catherine Tribouley, Michelle Graham, Brian Stoll, Maulik Patel, Mohammad Sahtout, Martha Blaney, Rachel Leibman, Talia Golan, Anthony Tolcher
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1- —AbbVie 10.13039/100006483
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsColorectal Cancer Treatments and Studies · Cancer Immunotherapy and Biomarkers · Neutropenia and Cancer Infections
In the published article, there were errors in Figure 4 as published. The graph included incorrect labeling of livmoniplimab doses for a few patients, including for the patient with deepest response (corrected from livmoniplimab 100mg to livmoniplimab 1500mg) in Figure 4B. The corrected Figure 4 and its caption appear below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.